$Avalo Therapeutics (AVTX.US)$
迄今为止表现不佳
在过去的几周里，我们看到了这个逐笔明细中出现了很多不寻常的活动。如果有人知道为什么AVTX的活动增加了，请告诉我。
在过去的几年里，把钱投到这家公司是有损失的赌注。任何一支处于长期下跌趋势的股票，通常都是我会远离的。
有趣的技术发展
在过去的几周里，...

By Julianna
Investors appear to be losing patience with Ark Investment Management's genomics fund.
$ARK生物基因科技革新主动型ETF (ARKG.US)$ is an actively managed ETF that focus on health care, information technology, materials, energy, and consumer discretionary.
Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business.
- according to ARKG fund description.
However, ARKG is down 30% this year as investors shun health-care stocks in favor for more cyclical names that perform well during an economic recovery. Even so, this ETF is faring far worse than the broader biotech sector, with the $道琼斯美国生物技术指数 (.DJUSBT.US)$up 11.35% this year.
ARKG is currently trading at $65.16 a share, 43% lower from its peak in this February. The genomics fund has also seen the largest outflows among Ark's ETFs this year.
It's interesting that typically loyal Ark investors have been bailing on the ETF.
The fund's assets have been chopped in half since February. While I don't believe the ETF is experiencing some of sort of 'doom loop,' clearly the outflows are putting downward price pressure on the underlying holdings and testing the will of remaining fund owners.
- said Nate Geraci, president of The ETF Store, an advisory firm.
FOLLOW ME to know more about ETFs
PLZ leave your comments and likes below
ARKG's top two holdings, $Teladoc Health (TDOC.US)$and $精密科学 (EXAS.US)$, heavily impact its performance, with drops of 47% and 33.5% this year, respectively.
The recent outflows may be due to investors looking for shorter-term opportunities into the year-end and freeing up cash.
- said Sylvia Jablonski, chief investment officer at Defiance ETFs.
Ark Chief Executive Officer Cathie Wood is well-known for prioritizing longer term investments over short-term gains.
This is a 5-10 year hold. AI in health care is going to change the way that we can predict, treat and manage the most difficult diseases like cancer, and the Ark fund gives investors access to the companies who are on the cutting edge of that research.
- Jablonski added.
Have you ever invested in the Biotechnology sector? Do you agree with Jablonski's opinion?
Source: Bloomberg